Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease
Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease
Thiopurine Metabolite Shunting in Late Pregnancy Increases the Risk of Intrahepatic Cholestasis of Pregnancy in Women With Inflammatory Bowel Disease, and Can be Managed With Split Dosing
Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation
Vedolizumab to prevent postoperative recurrence of Crohn’s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Reverse-engineered exclusive enteral nutrition in pediatric Crohn’s disease: A pilot trial
Submucosal Injection of the RNA Oligonucleotide GUT-1 in Active Ulcerative Colitis Patients: A Randomized, Double– Blind, Placebo-Controlled Phase 2a Induction Trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease
Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn’s disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial
Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a RandomizedControlled Trial
A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis